Rheumnow Podcast

Explore the complex relationship between obesity, inflammation, and rheumatic disease—and how excess adiposity may influence disease development, severity, treatment response, and patient outcomes.

In this expert-led discussion, leading clinicians and researchers examine how obesity can accelerate inflammatory and autoimmune rheumatic disease through metabolic, biomechanical, and immunologic pathways.

The panel explores the biology of adipose tissue and its role in systemic inflammation, including how obesity affects disease risk and progression, response to rheumatologic therapies, and the potential for weight loss and other interventions to reduce inflammation and improve clinical outcomes.

Expert Faculty:
• Juliana Simonetti, MD
• Lihi Eder, MD, PhD
• Naveed Sattar, MD, PhD
• Lee Kaplan, MD, PhD
• Jack Cush, MD — Moderator

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis.

The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Authors of the papers and experts will discuss the results of these trials, discuss how we consider obesity as both a comorbidity and part of the disease course, and share practical strategies for addressing obesity in everyday rheumatology practice.
Speakers: Dr. Philip Mease Dr. Tom Appleton Dr. Jack Cush (moderator)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control.

Join Amanda Mixon, PA-C, for a practical look at the role of the rheumatology advanced practice provider (APP) in recognizing and managing interstitial lung disease (ILD).

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.